Appendix 1 **EXPERTS FORM**

Please note that ◆ indicates a mandatory field

Title						
1. ◆ Family Name						
2. First Name						
3. • Nationality						
4. • Organisation/ Company Nam	e and	Professional A	ddress			
5. • Business Phone No (incl Int	Code)					
6. ♦ Business email address						
7. ♦ Passport number						
	lomas	and Drefession	al Affiliation	i		
8. • Qualifications - Degrees, Dip	iomas	and Profession	iai Amiliatioi	ns [.]		
 Present position and time sp 	ent in	current assigni	ment ⁱⁱ			
10. • General Category of Activities	H ⁱⁱⁱ	V iv	11. Sp	ecific Functional Expertise	H ⁱⁱⁱ	V i
MEDICINES EVALUATION Biologicals/Biotechnology products Chemicals Herbal/Traditional Products Inspections Pharmacovigilance Regulatory Affairs	_		QUALITY	Immunologicals/Biotechnolog product Vaccines Blood products Chemicals	у	
Other activity (please specify):						
	YES	NO _		Immunologicals/Biologicals Chemicals		
 Are you a member of staff of a competent authority? 	Ш		Environi	MENTAL RISK ASSESSMENT	_	
◆ Are you an external expert (e.g. University, hospital, member of staff			CLINICAL	Genetically Modified Organism	ns 🗌	
of another organisation, or a pharmaceutic etc)?	cal com	ipany,		Immunologicals/Biologicals Chemicals		
				covigilance and nagement		
			INSPECTI	ONS Laboratory Procedures GMP GCP		

GLP

12. Availability	13. Languages known:							
☐ Dossier Evaluation☐ Scientific Advice	please specify level, including your mother tongue	R	W	S				
☐ Guidelines ☐ Other								
☐ Ottlei								
	R: Read, W: Written, S: Spoken,							
	P: Poor, A: Average, G: Good, E: Excellent							

		14. Areas of Exper select main areas of			
	14.a Qu	ality		14.b F	Pre-Clinical
Chemistry: Analytical chemistry Synthetic chemistry Development pharmaceutics Stability Phytochemistry Radiopharmaceuticals Premixes for medicated feed production Drug/Device combinations Packaging Manufacture of medicines Peptide chemistry Medicinal gasses Structural similarity	Biology: Development genetics Genetic engineering: expression factor Cell culture - Fermentation Protein purification Protein analysis - characterisation; purity testing; biological assay Virology: validation of inactivation/removal steps; cell bank qualification; choice of viruses Microbiological testing Monoclonal antibodies Blood products Allergens Vaccines Gene therapy Cell therapy Tissue engineering Plant biotechnology Nanobiotechnology	Risk Assessment of GMOs: Vaccines Gene therapy/ biotechnology Transgenic plant	Manufacturing Process, Development and Validations: Blood products Biological products Biotechnology products Vaccines Cell therapy	Special tox In Repro Pharmaco and target Pharmaco Pharmaco Pathology Environme Assessme Residue si Behaviour Occupatio Microbiolo	xicology: onic toxicity, etc. xicology: ovitro toxicology Immunotoxicity oduction toxicity Genetic toxicity Carcinogenicity Toxicokinetics logy in laboratory animals dynamics kinetics ental Risk ont affety assessment al toxicology nal toxicology

			•	14.c	Clinical		
	(Please select 2 or 3 main areas only)						
П	AIDS		☐ Intensive care		☐ Ophthalmology ☐ Plastic Surgery		
	Anaesthesiology		☐ Internal medicine		☐ Organ transplantation ☐ Pneumology / Respiratory		
	Biostatistics		☐ Metabolic medicine				
	Cardiology		☐ Nephrology				
	Dermatology		☐ Neurology				
	Endocrinology		☐ Nuclear medicine		please specify: Radiology		
	Gastroenterology Genetics:		Oncology:		☐ Rheumatology ☐ Pain Paediatrics ☐ Stampatology		
Ш			Blood		☐ Pain Paediatrics ☐ Stomatology ☐ Pharmaceutical Medicine ☐ Urology		
	Pharmacogenetics Clinical Genetics		Breast CNS		□ Glology		
				· · · · · · · · · · · · · · · · · · ·	Vaccines.	_	
	Geriatrics		Gastro-inte		— Wilciobiology [
	Gynaecology/obstetrics	5	Gynaecolo	•	— Patriology — Mycology [
	Haematology		Head &	_	General nathology	_	
	Hepatology		Lung		Chemical pathology	Ш	
Ш	Immunology:		Renal	., ,	Haematology		
	Biological		Other (please	specity)	Histopathology		
_	Clinical						
Ш	Infectious diseases:	_					
ı	Microbiolog	~ —					
	Bacteriolog	· –					
	Parasitolog	· —					
	Mycology						
	Virology						
1							
					T		
14.d Target Species		14.e Pharmacovigilance and Risk					

14.d Target Species		14.e Pharmacovigilance and Risk Management				
Food producing animals:		☐ Epidemiology				
horses		☐ Pharmacoepidemiology				
cattle		☐ Phase I-III Safety Surveillance				
goats & sheep		☐ Phase IV and PMS Surveillance				
pigs		☐ Spontaneous reporting systems and databases				
poultry		☐ Drug utilisation				
fish □		☐ Statistics				
bees		☐ Terminology & coding				
rabbits		☐ Risk Communication				
☐ (Other) minor species		☐ Safety of Viral Vectors				
☐ Pet animals		☐ Atypical Infections/Zoonoses				
☐ Wild (zoo) animals		☐ Vaccine Safety				
		☐ Risk Management				

14.f Control/Inspections GMP/GLP/GCP								
Products:	GMP:		GLP:		GCP:			
Activities: Chemical Biological Biotechnology Immunologicals – Vaccines Immunologicals – Others Radiopharmaceuticals Other (please specify)	Active Substances Other Starting Materials Finished Product Control Laboratories Distributors Other (please specify)		Quality Systems/Assurander Documentation Joint Visits/Self Auditing Other (please specify)		Quality Systems - (sponsor) Trial Site Statistics Computer Systems Documentation Other (please specify)			
Active Substances Other Starting Materials Finished Product Market Surveillance Official Batch								

Do not refer to your CV in this box. Your main areas of expertise are to be addressed in section 14.

Please give a brief description of your qualification (e.g. MD, PhD and your specialisation). A Curriculum Vitae (CV) must be attached.

Please give a brief description of your current job position and indicate the year that you started your current assignment.

 $^{^{\}rm iii}$ Human domain.

iv Veterinary domain.